Media

Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates

Oncopeptides – Study confirms use of Pepaxti in a broader population, with strong data in the 50% of RRMM patients that suffer from reduced kidney function

Oncopeptides receives formal approval from Norwegian authorities to initiate Window-of-Opportunity study in glioblastoma

Emil Billbäck appointed new Chair of the Board of Intervacc

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Oncopeptides – COMy: New clinical and real-world evidence for Pepaxti demonstrating strong data and expanded positioning

Intervacc – Report from Annual General Meeting

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Intervacc – Interim report January – March 2026

Intervacc strengthens management team for future growth